biostudies-literatureRagnhildstveit AUS Department of Veterans Affairs, Clinical Sciences R&amp;DNCATS NIH HHSAmerican Foundation for Suicide PreventionBeth K and Stuart Yudofsky Chair in the Neuropsychiatry of Military Post Traumatic Stress Syndrome20451253231154125https://www.ebi.ac.uk/biostudies/studies/S-EPMC9989422biostudies-literatureUnknown13Posttraumatic stress disorder (PTSD) is a devastating condition, for which there are few pharmacological agents, often with a delayed onset of action and poor efficacy. Trauma-focused psychotherapies are further limited by few trained providers and low patient engagement. This frequently results in disease chronicity as well as psychiatric and medical comorbidity, with considerable negative impact on quality of life. As such, off-label interventions are commonly used for PTSD, particularly in chronic refractory cases. Ketamine, an <i>N</i>-methyl-D-aspartate (NDMA) receptor antagonist, has recently been indicated for major depression, exhibiting rapid and robust antidepressant effects. It also shows transdiagnostic potential for an array of psychiatric disorders. Here, we synthesize clinicTherapeutic advances in psychopharmacologyThe potential of ketamine for posttraumatic stress disorder: a review of clinical evidence.PMC9989422YIG-0-004-16IK2CX001873R01 DA030386UL1 TR001863Ragnhildstveit AAbdallah CGAverill LABass LCRoscoe JAverill CLfalseThe potential of ketamine for posttraumatic stress disorder: a review of clinical evidence.Posttraumatic stress disorder (PTSD) is a devastating condition, for which there are few pharmacological agents, often with a delayed onset of action and poor efficacy. Trauma-focused psychotherapies are further limited by few trained providers and low patient engagement. This frequently results in disease chronicity as well as psychiatric and medical comorbidity, with considerable negative impact on quality of life. As such, off-label interventions are commonly used for PTSD, particularly in chronic refractory cases. Ketamine, an <i>N</i>-methyl-D-aspartate (NDMA) receptor antagonist, has recently been indicated for major depression, exhibiting rapid and robust antidepressant effects. It also shows transdiagnostic potential for an array of psychiatric disorders. Here, we synthesize clinic2023-01-01T00:00:00Z20232025-04-19T02:38:45.172Z2025-02-19T04:43:51.915ZS-EPMC99894223689543110.1177/20451253231154125